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Abstract
Long-lived reservoirs of Human Immunodeficiency Virus (HIV) latently infected cells present the main barrier to a
cure for HIV infection. Much interest has focused on identifying strategies to activate HIV, which would be used
together with antiretrovirals to attack reservoirs. Several HIV activating agents, including Tumor Necrosis Factor
alpha (TNFa) and other agents that activate via NF-kB are not fully effective in all latent infection models due to
epigenetic restrictions, such as DNA methylation and the state of histone acetylation. DNA methyltransferases
(DNMT) inhibitors like 5-aza-2’deoxycytidine (Aza-CdR) and histone deacetylase (HDAC) inhibitors like Trichostatin A
(TSA) have been proposed as agents to enhance reactivation and have shown activity in model systems. However,
it is not clear how the activities of DNMT and HDAC inhibitors range across different latently infected cell lines,
potential models for the many different latently infected cells within an HIV patient. We determined HIV activation
following treatment with TNFa, TSA and Aza-CdR across a range of well known latently infected cell lines. We
assessed the activity of these compounds in four different Jurkat T cell-derived J-Lat cell lines (6.3, 8.4, 9.2 and 10.6),
which have a latent HIV provirus in which GFP replaces Nef coding sequence, and ACH-2 and J1.1 (T cell-derived),
and U1 (promonocyte-derived) cell lines with full-length provirus. We found that Aza-CdR plus TNFa activated HIV
at least twice as well as TNFa alone for almost all J-Lat cells, as previously described, but not for J-Lat 10.6, in
which TNFa plus Aza-CdR moderately decreased activation compared to TNFa alone. Surprisingly, a much greater
reduction of TNFa-stimulated activation with Aza-CdR was detected for ACH-2, J1.1 and U1 cells. Reaching the
highest reduction in U1 cells with a 75% reduction. Interestingly, Aza-CdR not only decreased TNFa induction of
HIV expression in certain cell lines, but also decreased activation by TSA. Since DNMT inhibitors reduce the activity
of provirus activators in some HIV latently infected cell lines the use of epigenetic modifying agents may need to
be carefully optimized if they are to find clinical utility in therapies aimed at attacking latent HIV reservoirs.
Findings
Despite the effectiveness of Highly Active Antiretroviral
Therapy (HAART) for Human Immunodeficiency Virus
type 1 (HIV-1) infection, patients cannot be cured due
to the persistence of long-lived reservoirs of cells
latently infected with HIV ([1-5] and reviewed in
[6-11]). Much interest has focused on attacking this
reservoir of HIV latently infected cells. A potentially
useful strategy, sometimes termed “shock and kill” [12],
aims to attack the latent reservoir treating patients with
HIV-activating agents to stimulate HIV replication in
the latently infected cells while blocking new infection
of cells with antiretrovirals.
One activation approach employs agents like phorbol
esters (e.g 12-O-Tetradecanoylphorbol-13-acetate (TPA),
prostratin) [13], interleukins (IL-2, IL-7) [14-18] and
cytokines (e.g. tumor necrosis factor alpha (TNFa)) [19]
that directly activate HIV gene expression via well-
known transcriptional activation pathways, like NF-B,
but many such agents are toxic or incompletely effective
in vivo [14,16,20,21]. Other approaches target the pro-
virus’ epigenetic environment, employing histone deace-
tylase (HDAC) inhibitors (HDACIs) like trichostatin A
(TSA) [22,23], suberoylanilide hydroxamic acid (SAHA)
[22,24], sodium butyrate [25,26], and valproic acid
[27,28], and/or DNA methyltransferase (DNMT) inhibi-
tors (DNMTIs) like 5-aza-2’deoxycytidine (Aza-CdR)
[29], with some strategies combining approaches [30]
(and reviewed in [6,31]). In addition, to increase the effi-
ciency of viral activators, combining the use of activators
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activator, as shown with buthionine sulfoximine [32]
may play a major role in optimizing treatment strategies.
Nucleosomes occupy specific positions on the HIV
LTR [22,33,34], with the nucleosome occupying the
position termed ‘nuc-1’ at a regulatory region of the
LTR 610 to 720 bp 3’ to the transcription start site hav-
ing significant inhibitory effects on HIV expression.
Chromatin condensed around nuc-1 in its deacetylated
form presents a block to HIV expression. Following
hyperacetylation and chromatin remodeling, mediated
by the recruitment of histone acetylases by transcription
factors binding directly or indirectly to the LTR, or by
Tat, the nuc-1 block is removed [22,33,35-37]. HDACIs,
by shifting histones to a more acetylated state facilitate
remodeling and removal of the block [38,39]. DNMTIs
likely activate HIV because, at least in some cells, the
LTR contains two CpG islands (particularly island 2)
that can be hypermethylated and the hypermethylated
DNA can recruit methyl-CpG binding domain (MDB)
protein family members, notably MDB2. MDB2
recruited to the LTR can serve a bridging function
between DNA and chromatin-modifying factors, such as
HDACs [29]. Several studies linked retroviral promoter
CpG methylation with transcription inactivation [40-42]
and cellular gene silencing [43]. DNMTIs can moder-
ately activate HIV alone, but in some systems they sig-
nificantly enhance agents, like TNFa,t h a td i r e c t l y
activate the HIV LTR, probably because activation is
limited due to proviral DNA hypermethylation
[29,44,45].
While DNMTIs and HDACIs significantly enhance
HIV activation in some latently infected cells, their abil-
ity to enhance activation across a wider range of latently
infected cells is currently unknown. The breadth of acti-
vating ability is important, since complete or close-to
complete eradication of latently infected cells may be
required to cure HIV infection. To better assess the
breadth of activity of activators representative of both
direct activators and activators acting via epigenetic
effects we surveyed the ability of three prototypical HIV
activating agents, the DNMTI Aza-CdR (2.5 μM), the
HDACI TSA (1.5 μM), and TNFa (10 ng/ml), activating
via NF-B, in a panel of widely used HIV latently
infected model cell lines, including the J-Lat series
derived from Jurkat T-cells [46], J1.1 [47], also a Jurkat
derivative, ACH-2 [48], derived from the A3.01 T lym-
phocytoid cell line, and U1 [49], derived from the U937
promonocytic cell line. The concentrations used for
TSA and TNFa were optimized to obtain the best acti-
vation profile in combination with Aza-CdR. A dose
response curve with J-Lat 6.3 cells was performed to
determine the minimum concentration required where
the activation reached a plateau (data not shown). We
employed this plateau concentration in subsequent stu-
dies to assess the effects of combined treatments with
different agents used at their maximally effective con-
centrations, since the object of any latency activation
s t r a t e g yw o u l db et od e t e r m i n eh o wt oa c h i e v eam a x i -
mal degree of provirus activation.
J-Lat cells harbor an HIV provirus containing the
Green Fluorescent Protein (GFP) ORF instead of nef
and a frameshift mutation in env [46]. With GFP under
the control of the HIV LTR, activation is conveniently
monitored via flow cytometry. HIV production in J-Lat
cells can also be determined by p24 antigen (p24) quan-
tification. Different J-Lat lines exhibit different activation
patterns when treated with TNFa, likely due to different
integration sites and accompanying epigenetic states
[46]. J-Lat cells have contributed significantly to latency
studies, including the identification of the methyl-CpG
binding domain protein 2 (MBD2), a transcriptional
repressor that binds to methylated DNA, as a regulator
of HIV latency, which suggested that DNMTIs like Aza-
CdR might activate latent provirus [29]. Moreover, LTR
demethylation, after Aza-CdR treatment, correlated with
a synergistic increase of proviral activation when com-
bined with TNFa in J-Lat 6.3, 8.4, 9.2 and 15.4. ACH-2,
U1 and J1.1 harbor full-length proviruses, without GFP
replacing coding sequence (although J1.1 has defects in
signalling through CD3, ACH-2 has a point mutation in
the Tat responsive element (TAR) [50], and U1 contains
mutations in Tat [51]). Flow cytometric evaluation of
activation is not possible in these lines, but they can be
monitored using assays for HIV gene products (e.g.
p24).
Before embarking on a survey of the activators across
cell lines, we undertook further optimization experi-
ments, initially performing order-of-addition experi-
ments using J-Lat 6.3 (Fig.1), in which Aza-CdR had
been shown to enhance activation mediated by TNFa
[29], since inhibiting DNA methylation well before addi-
tion of the direct transcriptional activator TNFa could
be required for maximal activation. Detection and quan-
tification of GFP positive cells from a live-gated popula-
tion was performed at 48 h using a FACScalibur
cytometer (BD Biosciences, San Jose CA), analyzed with
Cell Quest Pro software (BD Biosciences, San Jose CA).
As has been previously reported, we found that Aza-
CdR alone did not activate [29], but TNFa alone pro-
duced significant increases in GFP positive cells, and
Aza-CdR enhanced activation with TNFa treatment. We
calculated the fold increase of activation due to Aza-
CdR, that is the activation observed with TNFa plus
Aza-CdR divided by the activation with TNFa alone
(TNFa+Aza-CdR/TNFa, (FI-Aza)), which expresses the
fold increase due to the addition of Aza-CdR. FI-Aza
showed that the greatest activation occurred when J-Lat
Fernandez and Zeichner Virology Journal 2010, 7:266
http://www.virologyj.com/content/7/1/266
Page 2 of 106.3 cells were treated with both compounds simulta-
neously (FI-Aza:3.8). Although there were differences in
the extent of activation that depended on the order of
addition, Aza-CdR always enhanced activation of J-Lat
6.3 by TNFa, with FI-Aza ranging between 3.8 and 1.9.
To determine when Aza-CdR most enhanced TNFa
or TSA activation, a time-course experiment was per-
formed using J-Lat 6.3 cells. Percent GFP positive cells
using FACS analysis (Fig. 2A) and p24 production using
an enzyme-linked immunosorbent assay (ELISA) (Perkin
Elmer, Waltham, MA) (Fig. 2B) were determined for all
time points and treatment conditions. Aza-CdR in com-
bination with TNFa reached its maximum effect at 48 h
post-induction when per cent GFP positive cells where
quantified. Moreover, p24 production did not increase
significantly beyond 48 h, losing Aza-CdR’s enhancing
effect when combined with TNFa at later time points.
Due to the lack of synergy between TSA and Aza-CdR
Figure 1 Optimization of J-Lat 6.3 cells activation by TNFa/Aza-CdR. HIV latently infected J-Lat 6.3 cells that contain the GFP reporter gene
were (A) treated with Aza-CdR (2.5 μM) and TNFa (10 ng/ml) for 48 h, (B) were treated with Aza-CdR plus TNFa and then washed at 24 h, (C)
treated with Aza-CdR followed by addition of TNFa after 24 h of Aza-CdR treatment, and (D) treated with Aza-CdR plus TNFa for 24 h, followed
by the addition of fresh Aza-CdR. Cells were cultured in RPMI (Atlanta Biologicals, Lawrenceville, GA) with 10% FBS (Invitrogen, Carlsbad, CA).
Two million cells were seeded with 3 ml medium in six well plates and treated with Aza-CdR (2.5 μM), TNFa (10 ng/ml) or both compounds
combined. After 48 h cells were transferred to a 15 ml conical tube and spun down at 1400 rpm for 7 min. The supernatant was discarded and
cell pellets were resuspended and were washed twice with chilled 1× PBS and fixed in 2% formaldehyde for FACS analysis using a FACScalibur
cytometer (BD Biosciences, San Jose CA) and analyzed with Cell Quest Pro software (BD Biosciences, San Jose CA). GFP positive cells from the
live population, defined by forward versus side scatter gating, were quantified. 20.000 events per treatment condition were analyzed. Results are
the mean ± standard deviation (SD). The TNFaAza-CdR/TNFa (FI-Aza) ratio was calculated and used to evaluate the optimum time of activator
addition.
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Page 3 of 10Figure 2 Time-course activation by TNFa and TSA alone or in combination with Aza-CdR in J-Lat 6.3 cells.A .G F Pp o s i t i v ec e l l
quantification by FACS analysis at 24, 48 and 72 h post-induction for all treatments and treatment combinations using J-Lat 6.3 cell line. GFP
positive cells from the live population, defined by forward versus side scatter gating, were quantified. 20.000 events per treatment condition
were analyzed. B. p24 antigen production determined using an enzyme-linked immunosorbent assay (ELISA) (Perkin Elmer, Waltham, MA) for all
post-induction time points and treatments as for panel A. C. Cell viability of the different treatments and treatment combinations for all time
points determined with MTS assay (Promega, Madison, WI). Final activator compound concentrations were, for Aza-CdR (2.5 μM), TNFa (10 ng/
ml) and TSA (1.5 μM). Results are the mean ± standard deviation (SD).
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Page 4 of 10we determined 48 h to be the best time point to analyze
further data based on TNFa plus Aza-CdR results. Cell
viability for all time points and treatment conditions
(Fig. 2C) were performed using MTS assay (Promega,
Madison, WI). TNFa alone does not strongly activate
J-Lat 6.3, 8.4 and 9.2 cells, as shown in Fig. 3A, and as
reported [29]. TNFa can, at most, achieve 20% activa-
tion in these three cell lines. In contrast, in J-Lat 10.6,
TNFa activates ~80% of the cells, which enabled us to
determine the effect of combining Aza-CdR with TNFa
and TSA when the provirus is highly activated by
TNFa.S u r p r i s i n g l y ,t h ec o m bination of Aza-CdR and
TNFa did not increase or maintain activation in J-Lat
10.6, but instead moderately decreased activation (p ≤
0.1) (Fig. 3B) in per cent GFP positive cells while activa-
tion from the combination of Aza-CdR and TNFa was
significantly lower when p24 was determined (p ≤ 0.05)
( F i g .3 C ) .T h er e d u c t i o no factivation in J-Lat 10.6 sug-
gested that Aza-CdR could have, in some latently
infected cells, a detrimental effect when combined with
an activator, particularly when activation via other path-
ways, such as those stimulated by TNFa,i sg r e a t( F i g .
3C). Cell viability did not differ between TNFa and
Aza-CdR, alone or in combination (Fig. 3D), so cell toxi-
city could not account for the observations. Of note, we
did not detect a synergistic effect when TNFa and TSA
were combined when percent GFP positive cells were
quantified. As shown in the time-course experiment in
Fig. 2 this synergy can be detected in earlier time points
but not at 48 h post-induction when Aza-CdR reaches
maximal effect. When p24 production is determined, we
only could see this TSA-TNFa synergy in J-Lat 8.4 cells
because TNFa activation in this cell line is strongly
blocked (Fig. 3C).
To assess how the combinations of Aza-CdR, TNFa,
and TSA affect HIV activation in other HIV latently
infected cells, we studied the ability of these agents,
alone and together, to activate HIV in ACH-2, U1 and
J1.1 cells (Fig. 4A), other lines in which TNFa strongly
activates HIV expression [52]. Since these cells harbor
a latent HIV provirus that does not have nef replaced
with GFP, we assessed activation by measuring p24 48
h after treatment with the activators using ELISA (Per-
kin Elmer, Waltham, MA). TNFa powerfully activated
HIV expression in these cells, as previously described,
but as we observed with J-Lat 10.6, treating ACH-2,
U1 and J1.1 cells with Aza-CdR significantly decreased
activation by TNFa, from 23% (J1.1, p ≤ 0.05) to 40%
(ACH-2, p ≤ 0.05), to 75% (U1, p ≤ 0.05). In ACH-2
cells, but not in any other of the cell lines studied,
Aza-CdR also significantly decreased activation follow-
ing treatment with TSA alone (57%, p ≤ 0.05), or TSA
+TNFa (45%, p ≤ 0.05). Impaired cell viability, as with
J-Lat cells, could not explain this reduction in
activation (Fig. 4B). Thus, in certain circumstances, a
DNMTI can decrease activation by agents acting both
through the NF-B pathway and mediated by an
HDACI. However, a decrease in activation produced
by Aza-CdR was not observed in all the non-J-Lat cell
lines under all conditions. In J1.1 cells, Aza-CdR did
not decrease activation by TSA or TSA plus TNFa.
Overall, the ability of the DNMTI Aza-CdR to help
activate HIV replication (or to inhibit the activation
produced by other agents) exhibited a strong cell line
dependence: In U1 and J1.1 cell lines, Aza-CdR inhib-
ited activation by TNFa,b u tn o tb yT S Ao rT N F a
plus TSA, while in ACH-2 cells Aza-CdR inhibited
activation by both TNFa and TSA when used alone or
in combination. Table 1 summarizes the effect of Aza-
CdR and TNFa when added simultaneously in all
latently infected cells tested, highlighting that the
effects due to the combination of agents may be detri-
mental or helpful, depending on the cell line studied.
The data presented in this report complements the
findings by Kauder et al. [29] and Blaskova et al. [44]
regarding the effects of Aza-CdR in activating latently
infected cells. In those studies, cell lines H12 and
2D12 [44] and all the J-Lat clones except for A2 clone
[29] showed increased activation with Aza-CdR used in
combination with TNFa in comparison with TNFa
alone (the A2 clone showed the same levels of activa-
tion with or without Aza-CdR). The detrimental effect
we observed with Aza-CdR in certain latently infected
cell lines induced by viral activators like TNFa (ACH-
2, J1.1 and U1) highlights the complexity of HIV reac-
tivation, the importance of studies utilizing a broad
range of cell lines, and the broad range of effects that
may be observed in different infected cells.
The differential effects on HIV activation of epigenetic
agents may not be entirely unexpected, since the chro-
matin structure of the LTR can differ for the proviruses
integrated into one cell line or another [53]. It will
require much additional work to understand the
mechanisms responsible for the differential responses to
epigenetic activators, but a few potential explanations
may be considered. Aza-CdR may have complicated
effects, since the activation of some genes may inhibit
others [54-56], so differences in the methylation and
hence activation state of cellular genes in the latently
infected cell lines could account for the differences in
activation observed with Aza-CdR: In J-Lat 6.3, 8.4 and
9.2 cells, Aza-CdR may have direct effects, leading to
the demethylation of the LTR, enhancing activation,
while in the other lines Aza-CdR may help activate
other cellular genes that directly or indirectly inhibit
HIV activation, since differential expression of certain
cellular genes can be associated with the maintenance of
latency [57,58].
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Page 5 of 10Figure 3 HIV activation by TNFa and TSA alone or in combination with Aza-CdR in four J-Lat cell lines. A. GFP positive cell quantification
by FACS analysis at 48 h post-induction of J-Lat 6.3, 8.4, 9.2 and 10.6 cell lines treated with TNFa or Aza-CdR alone or in combination. 20.000
events from the live population defined by forward versus side scatter gating were analyzed. B. Proviral activation as determined by percent GFP
positive cells for the different treatments and treatment combinations in the four J-Lat cells (J-Lat 6.3, 8.4, 9.2 and 10.6 indicated on each panel).
C. p24 antigen production for all treatments and treatment combinations at 48 h post-induction. D. Cell viability of the different treatments and
treatment combinations determined with an MTS assay (Promega, Madison, WI) at 48 h. Cells were cultured in RPMI with 10% FBS. Two million
cells were seeded and treated with the different compounds for 48 h. The compound order of addition was determined as described in Fig. 1:
agents were added at time 0 h, with no further additional steps. After 48 h, cells were washed twice with chilled 1× PBS and fixed in 2%
formaldehyde as in the FACS analysis described in the Fig. 1 legend. At the same time, supernatants from the different treatment conditions
were stored at -80°C until further use. p24 antigen was determined using ELISA (Perkin Elmer, Waltham, MA) from the stored supernatants. Final
activator compound concentrations were, for Aza-CdR (2.5 μM), TNFa (10 ng/ml) and TSA (1.5 μM). Results are the mean ± standard deviation
(SD). Statistical analysis (Student’s t-test) was performed using the STATA software package (StataCorp LP, College Station, TX), * p ≤ 0.05.
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Page 6 of 10Figure 4 HIV activation by TNFa and TSA in ACH-2, U1, and J1.1 latently infected cell lines with or without Aza-CdR. A. p24 antigen
production in ACH-2, U1 and J1.1 cell lines for all treatments and treatment combinations at 48 h post-induction. Cells were cultured in RPMI
with 10% FBS. 2 million cells were treated with the different compounds for 48 h. The compound order of addition was determined in Fig. 1.
After 48 h, cells were pelleted at 1400 rpm for 7 min and discarded. Supernatants from the different treatment conditions were stored at -80°C
until further use. p24 antigen was determined using ELISA (Perkin Elmer, Waltham, MA) from the stored supernatants. B. Cell viability of the
different treatments and treatment combinations shown in panel A, determined with an MTS assay (Promega, Madison, WI) at 48 h post-
treatment. Compound final concentrations of the activators were Aza-CdR (2.5 μM), TNFa (10 ng/ml) and TSA (1.5 μM). Results are the mean ±
standard deviation (SD). Statistical analysis (Student’s t-test) was performed using STATA software package (StataCorp LP, College Station, TX),
*p≤ 0.05.
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Page 7 of 10In HIV infected patients, the latently infected cells
harbor many different proviruses. While the frequency
of latently infected cells in the periphery is low, perhaps
1i n1 0
6 cells, the total number of latently infected cells
within a patient has been estimated to be as high as
10
6-10
7 total cells [59]. The latently infected lines we
examined may not be completely representative of
latently infected cells as they exist in vivo,b u tt h eg r e a t
potential variability in host cell chromosomal location
and epigenetic and transcriptional environments of pro-
v i r u s e sf r o ma sm a n ya s1 0
6-10
7 total latently infected
cells suggests that, at least for some latently infected
cells that exist in vivo, DNMTIs and HDACIs may inhi-
bit HIV activation, as we describe here. While it is clear
that DNMTIs and HDACIs offer promise as agents to
attack the reservoir, our findings suggest that it may be
necessary to carefully optimize HIV activation strategies
so that some treatment or combination of treatments is
active across large numbers of latently infected cells. For
effective clinical applications, fairly elaborate combina-
tions of activators and co-activators may be required to
assure that essentially all proviruses are induced into
active replication.
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Mean p24 (pg/ml) ± standard deviation.
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